Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

NCT03134222 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT03134222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03134222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
May 24, 2017
Completion date
December 18, 2019
Enrollment
47 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous lupus erythematosus